251 related articles for article (PubMed ID: 16368866)
1. Optimizing first-line treatment options for patients with advanced NSCLC.
Wakelee H; Belani CP
Oncologist; 2005; 10 Suppl 3():1-10. PubMed ID: 16368866
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of the unresectable non small cell lung carcinoma].
Spásová I
Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
[TBL] [Abstract][Full Text] [Related]
3. [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
Langer F; Helsberg K; Schütte WH; Leschinger MI
Onkologie; 2005 Mar; 28 Suppl 1():1-28. PubMed ID: 15802886
[TBL] [Abstract][Full Text] [Related]
4. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel.
Gridelli C; Aapro M; Ardizzoni A; Balducci L; De Marinis F; Kelly K; Le Chevalier T; Manegold C; Perrone F; Rosell R; Shepherd F; De Petris L; Di Maio M; Langer C
J Clin Oncol; 2005 May; 23(13):3125-37. PubMed ID: 15860872
[TBL] [Abstract][Full Text] [Related]
5. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature.
Grossi F; Aita M; Follador A; Defferrari C; Brianti A; Sinaccio G; Belvedere O
Oncologist; 2007 Apr; 12(4):451-64. PubMed ID: 17470688
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy for advanced stage non-small cell lung cancer.
Fathi AT; Brahmer JR
Semin Thorac Cardiovasc Surg; 2008; 20(3):210-6. PubMed ID: 19038730
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic strategy for treatment of metastatic non-small cell lung cancer.
Berhoune M; Banu E; Scotte F; Prognon P; Oudard S; Bonan B
Ann Pharmacother; 2008 Nov; 42(11):1640-52. PubMed ID: 18957625
[TBL] [Abstract][Full Text] [Related]
8. Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel.
Belani CP
Lung Cancer; 2005 Dec; 50S2():S3-S8. PubMed ID: 16551520
[TBL] [Abstract][Full Text] [Related]
9. Challenges in advanced NSCLC: optimizing platinum-based chemotherapy and treating special populations.
Belani CP
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S10-22. PubMed ID: 19780242
[TBL] [Abstract][Full Text] [Related]
10. First-line combination chemotherapy for advanced non-small cell lung cancer: the Eastern Cooperative Oncology Group and Southwest Oncology Group experience.
Sandler A
Semin Oncol; 1999 Oct; 26(5 Suppl 15):44-51. PubMed ID: 10566611
[TBL] [Abstract][Full Text] [Related]
11. A multicenter phase II study of sequential vinorelbine and cisplatin followed by docetaxel and gemcitabine in patients with advanced non-small cell lung cancer.
Pallis AG; Agelidou A; Papakotoulas P; Tsaroucha A; Agelidou M; Agelaki S; Androulakis N; Vamvakas L; Gerogianni A; Kotsakis A; Kentepozidis N; Georgoulias V
Lung Cancer; 2006 May; 52(2):165-71. PubMed ID: 16563559
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
[TBL] [Abstract][Full Text] [Related]
13. [State-of-the art treatment of locally advanced and metastatic non-small cell lung cancer].
Bunn PA
Anticancer Drugs; 2001 Jul; 12 Suppl 3():S3-8. PubMed ID: 11556251
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy in metastatic and locally advanced non-small cell lung cancer.
Spigel DR; Greco FA
Semin Surg Oncol; 2003; 21(2):98-110. PubMed ID: 14508860
[TBL] [Abstract][Full Text] [Related]
15. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Langer CJ; Natale RB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
[TBL] [Abstract][Full Text] [Related]
16. [Stage IV non small cell bronchial carcinoma; first line therapy in 2007].
Lemarié E
Rev Mal Respir; 2007 Oct; 24(8 Pt 2):6S101-7. PubMed ID: 18235401
[TBL] [Abstract][Full Text] [Related]
17. Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy.
Hotta K; Fujiwara Y; Matsuo K; Suzuki T; Kiura K; Tabata M; Takigawa N; Ueoka H; Tanimoto M
Cancer; 2007 Mar; 109(5):939-48. PubMed ID: 17285602
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of monoclonal antibodies in non small cell lung cancer.
Filipits M
J BUON; 2009 Sep; 14 Suppl 1():S147-52. PubMed ID: 19785057
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer.
Di Maio M; Chiodini P; Georgoulias V; Hatzidaki D; Takeda K; Wachters FM; Gebbia V; Smit EF; Morabito A; Gallo C; Perrone F; Gridelli C
J Clin Oncol; 2009 Apr; 27(11):1836-43. PubMed ID: 19273711
[TBL] [Abstract][Full Text] [Related]
20. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
